Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Bressler NM, et al. Among authors: koester j. Arch Ophthalmol. 2002 Nov;120(11):1443-54. doi: 10.1001/archopht.120.11.1443. Arch Ophthalmol. 2002. PMID: 12427056 Clinical Trial.
Improvement after verteporfin therapy.
Anand R, Bressler NM, Bressler SB, Gray TE, Harvey P, Haynes L, Koester JM, Manos KS, Miller JW, Murphy S, Reaves A, Sickenberg M, Singerman LJ, Strong A, Stur M; "Improvement After Verteporfin Therapy" Writting Committee for TAP Study Group. Anand R, et al. Among authors: koester jm. Arch Ophthalmol. 2003 Mar;121(3):415-6. doi: 10.1001/archopht.121.3.415. Arch Ophthalmol. 2003. PMID: 12617718 No abstract available.
Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
Pieramici DJ, Bressler SB, Koester JM, Bressler NM. Pieramici DJ, et al. Among authors: koester jm. Arch Ophthalmol. 2006 May;124(5):660-4. doi: 10.1001/archopht.124.5.660. Arch Ophthalmol. 2006. PMID: 16682587
Effect of adjunctive diclofenac with verteporfin therapy to treat choroidal neovascularization due to age-related macular degeneration: phase II study.
Adjunctive Diclofenac with Verteporfin (ADD-V) Study Group; Boyer DS, Beer PM, Joffe L, Koester JM, Marx JL, Weisberger A, Yoser SL. Adjunctive Diclofenac with Verteporfin (ADD-V) Study Group, et al. Retina. 2007 Jul-Aug;27(6):693-700. doi: 10.1097/IAE.0b013e318030e519. Retina. 2007. PMID: 17621177 Clinical Trial.
Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.
Nittala MG, Metlapally R, Ip M, Chakravarthy U, Holz FG, Staurenghi G, Waheed N, Velaga SB, Lindenberg S, Karamat A, Koester J, Ribeiro R, Sadda S. Nittala MG, et al. Among authors: koester j. JAMA Ophthalmol. 2022 Mar 1;140(3):243-249. doi: 10.1001/jamaophthalmol.2021.6067. JAMA Ophthalmol. 2022. PMID: 35113137 Free PMC article. Clinical Trial.
90 results